Analyst's mean target price for TXMD is $16.14 while analysts mean recommendation is 1.90. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. American International Group Inc. now owns 92,415 shares of the company's stock valued at $665,000 after buying an additional 6,103 shares during the last quarter.
Several equities analysts recently commented on TXMD shares. (NASDAQ:EBAY) to report $ 0.48 EPS and has got OUTPERFORM rating from 8 of Thomson Reuters analysts and 2 analyst (s) given UNDERPERFORM rating. Cantor Fitzgerald reissued an "overweight" rating and issued a $33.00 target price on shares of TherapeuticsMD in a report on Wednesday, May 10th.
TherapeuticsMD Inc (NYSEMKT:TXMD) was upgraded by Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating in a note issued to investors on Tuesday, StockTargetPrices.com reports. They now have a United States dollars 15 price target on the stock. Stifel Nicolaus reiterated a "buy" rating and issued a $20.00 target price on shares of TherapeuticsMD in a research report on Thursday, May 25th.
COPYRIGHT VIOLATION WARNING: This story was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of USA & worldwide trademark & copyright laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/07/17/american-international-group-inc-boosts-stake-in-therapeuticsmd-inc-nasdaqtxmd-updated.html.
TherapeuticsMD (NASDAQ:TXMD) opened at 5.63 on Tuesday. The current share price indicates that stock is -3.00% away from its one year high and is moving 12.04% ahead of its 52-week low. The company's 50-day moving average price is $4.62 and its 200 day moving average price is $5.62.
The Coca-Cola Company (NYSE:KO)'s stock on Friday traded at beginning with a price of $44.52 and when day-trade ended the stock finally popped up 0.56% to reach at $44.68. Raymond James Financial Services Advisors Inc. raised its position in TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company's stock valued at $207,000 after buying an additional 10,330 shares during the period. Finally, Greenwood Capital Associates LLC raised its stake in shares of TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company's stock worth $146,000 after buying an additional 3,022 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of TherapeuticsMD by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company's stock valued at $98,827,000 after buying an additional 329,245 shares during the last quarter. Stifel Financial Corp raised its position in shares of TherapeuticsMD by 125.4% in the first quarter.